|
Study
|
Number of patients (GFR < 60)
|
Age
|
Male (%)
|
BMI
|
sBP (mmHg)
|
dBP (mm Hg)
|
HgbA1c (%)
|
GFR < 30 (%)
|
GFR 30-45 (%)
|
GFR 45-60 (%)
|
Median GFR in CKD
|
UACR (mg/g)
|
Noormo-albuminuria (%)
|
Microalbuminuria (%)
|
Macroalbuminuria (%)
|
|---|
|
SGLT2i vs placebo
|
|
CANVAS Program
|
2039
|
67.6
|
58.2
|
32.3
|
138
|
75
|
8.2
|
0.0
|
27.2
|
72.8
|
49.1
|
24.4
|
55.4
|
N/A
|
N/A
|
|
CREDENCE
|
2592
|
63.8
|
66.5
|
31.3
|
140
|
78
|
8.2
|
0.0
|
45.3
|
48.1
|
45.1
|
1012
|
N/A
|
N/A
|
N/A
|
|
DECLARE-TIMI 58
|
1265
|
67.3
|
64.3
|
34.5
|
134
|
75
|
8.2
|
N/A
|
N/A
|
N/A
|
51.4
|
N/A
|
55.6
|
30.9
|
13.5
|
|
EMPA-REG OUTCOME
|
1819
|
67.1
|
72.8
|
30.6
|
138
|
76
|
8.1
|
0
|
31.3
|
68.7
|
N/A
|
N/A
|
47.7
|
33.9
|
18.4
|
|
SCORED
|
10,584
|
69.0
|
55.1
|
31.8
|
138
|
78
|
8.3
|
7.7
|
43.9
|
48.3
|
44.5
|
74.5
|
35.1
|
33.9
|
31.0
|
|
VERTIS-CV
|
1807
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
|
Weighted average (SGLT-2 inhibitors)
|
67.8
|
59.5
|
31.9
|
137.9
|
77.2
|
8.2
| |
40.8
|
53.4
| | |
40.8
|
33.6
|
27.7
|
|
GLP-1 RA vs placebo
|
|
ELIXA
|
1399
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
59.7
|
25.5
|
14.8
|
|
EXSCEL
|
3177
|
66.5
|
57.1
|
32.8
|
N/A
|
N/A
|
8.1
|
0
|
28.0
|
72.0
|
49.2
|
N/A
|
71.4
|
19.6
|
9.0
|
|
HARMONY Outcomes
|
2222
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
|
LEADER
|
2158
|
67.3
|
61.3
|
32.7
|
136.4
|
75.1
|
8.6
|
10.4
|
29.0
|
60.6
|
45.6
|
49.5
|
47.6
|
29
|
23.4
|
|
PIONEER-6
|
856
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
|
REWIND
|
2199
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
|
SUSTAIN-6
|
832
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
|
Weighted average (GLP-1 RAs)
|
66.8
|
58.8
|
32.8
| | |
8.3
| |
28.4
|
67.4
| | |
61.3
|
23.8
|
14.8
|
- Normoalbuminuria, microlabuminuria and macroalbuminuria defined as < 30, 30–299, and ≥ 300 mg/g creatinine, respectively
- SGLT2i sodium-glucose cotransporter-2 inhibitors, GLP-1 RAs glucagon-like peptide-1 receptor agonists, GFR glomerular filtration rate, BMI body mass index, sBP systolic blood pressure, dBP diastolic blood pressure, Hgb A1c hemoglobin A1c, UACR urine albumin-to-creatinine ratio, N/A not available
